This online seminar will outline a target enrichment technology to improve next generation sequencing assays for cancer research. NGS is increasingly being used to support cancer clinical trials and translational research. However, these NGS cancer solutions often suffer from a number of limitations. Personalis addresses these issues using its Accuracy and Content Enhanced (ACE) technology to improve cancer panel, exome, transcriptome sequencing. The ACE extended cancer panel and ACE cancer exome capture more than 1,600 cancer genes as well as key noncoding regions. DNA data at high coverage provides sensitive detection of small variants and CNVs at low allele frequencies. RNA data from the same sample, targeted to the same gene set, is used to detect gene fusions, confirm allelic expression, and quantify gene expression.